Optimeos Life Sciences, Inc.
Princeton, NJ · Founded 2016 · CIK 0001819114 · Biotech · Private
Non-viral gene delivery platform for gene replacement therapy
optimeos.com →- Grants
- $3.1M
- 7 awards
- Sector median: 1
- Raised
- $3.3M
- 4 Form D · Jun 2026
- 4 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 0 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · STTR Phase I: Sustained Delivery of Peptides with Inverse Flash Nanoprecipitation | $225,000 | |
| Private capital raised | Form D · SEC | $270,000 | |
| Federal grant | National Science Foundation · Phase I · STTR Phase I: Formulation of a COVID-19 mRNA Vaccine by Inverse Flash NanoPrecipitation | $256,000 | |
| Private capital raised | Form D · SEC | $175,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Sustained Release Formulations of Therapeutic Antibodies | $255,351 | |
| Federal grant | Department of Health and Human Services · Phase I · Highly loaded long-acting depots of therapeutic peptides | $287,726 | |
| Private capital raised | Form D · SEC | $1,875,004 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II:Formulation of a mRNA-Based Therapy for CTLN1 by Inverse Flash NanoPrecipitation | $1,500,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted delivery of nucleic acid formulations for in vivo CAR-Treg generation | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · In vivo targeted delivery of nucleic acids to hematopoietic stem cells for treating primary immunodeficiencies | $300,000 | |
| Private capital raised | Form D · SEC | $1,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3317 | Actinium Pharmaceuticals, Inc. | — | $3.3M |
| 3318 | ImmunoGen | — | — |
| 3319 | Cypre, Inc. | — | $3.2M |
| 3320 | Optimeos Life Sciences, Inc. | — | $3.3M |
| 3321 | Applied Proteomics, Inc. | — | $50M |
| 3322 | DNA SEQ 2, INC. | — | $1.2M |
| 3323 | Clasp Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Benjamin DoranzDirector
- Shahram HejaziDirector · Executive Officer
- Shahram Hejazi, PhDDirector · Executive Officer
- Robert Prud'hommeDirector
- Robert Prud'homme, PhDDirector
- Jason SmithDirector
- Jason Smith, PhDDirector
Patents
- Nanoparticles And Methods Of Production For The Encapsulation Of Nucleic Acidsapplication
- Targeted Nanoparticles Encapsulating Water-soluble Therapeutics, Methods Of Production, And Useapplication
- Nanoparticles And Methods Of Production For The Encapsulation Of Nucleic Acidsapplication
- Nanoparticles And Methods Of Production For The Encapsulation Of Nucleic Acidsapplication
- Nanoparticles And Methods Of Production For The Encapsulation Of Nucleic Acidsapplication
- Nanoparticles And Methods Of Production For The Encapsulation Of Nucleic Acidsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.